Literature DB >> 16794566

Report by the ACNP Task Force on response and remission in major depressive disorder.

A John Rush1, Helena C Kraemer, Harold A Sackeim, Maurizio Fava, Madhukar H Trivedi, Ellen Frank, Philip T Ninan, Michael E Thase, Alan J Gelenberg, David J Kupfer, Darrel A Regier, Jerrold F Rosenbaum, Oakley Ray, Alan F Schatzberg.   

Abstract

This report summarizes recommendations from the ACNP Task Force on the conceptualization of remission and its implications for defining recovery, relapse, recurrence, and response for clinical investigators and practicing clinicians. Given the strong implications of remission for better function and a better prognosis, remission is a valid, clinically relevant end point for both practitioners and investigators. Not all depressed patients, however, will reach remission. Response is a less desirable primary outcome in trials because it depends highly on the initial (often single) baseline measure of symptom severity. It is recommended that remission be ascribed after 3 consecutive weeks during which minimal symptom status (absence of both sadness and reduced interest/pleasure along with the presence of fewer than three of the remaining seven DSM-IV-TR diagnostic criterion symptoms) is maintained. Once achieved, remission can only be lost if followed by a relapse. Recovery is ascribed after at least 4 months following the onset of remission, during which a relapse has not occurred. Recovery, once achieved, can only be lost if followed by a recurrence. Day-to-day functioning and quality of life are important secondary end points, but they were not included in the proposed definitions of response, remission, recovery, relapse, or recurrence. These recommendations suggest that symptom ratings that measure all nine criterion symptom domains to define a major depressive episode are preferred as they provide a more certain ascertainment of remission. These recommendations were based largely on logic, the need for internal consistency, and clinical experience owing to the lack of empirical evidence to test these concepts. Research to evaluate these recommendations empirically is needed.

Entities:  

Mesh:

Year:  2006        PMID: 16794566     DOI: 10.1038/sj.npp.1301131

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  185 in total

1.  Developing Cognitive Behavioral Therapy to Prevent Depressive Relapse in Youth.

Authors:  Beth D Kennard; Sunita M Stewart; Jennifer L Hughes; Robin B Jarrett; Graham J Emslie
Journal:  Cogn Behav Pract       Date:  2008-11-01

2.  Measurement-based care for unipolar depression.

Authors:  David W Morris; Madhukar H Trivedi
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

3.  The prognostic significance of subsyndromal symptoms emerging after remission of late-life depression.

Authors:  D N Kiosses; G S Alexopoulos
Journal:  Psychol Med       Date:  2012-05-21       Impact factor: 7.723

4.  The responsiveness of the different versions of the Hamilton Depression Scale.

Authors:  Per Bech
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

5.  A randomized clinical trial of a telephone depression intervention to reduce employee presenteeism and absenteeism.

Authors:  Debra Lerner; David A Adler; William H Rogers; Hong Chang; Annabel Greenhill; Elina Cymerman; Francisca Azocar
Journal:  Psychiatr Serv       Date:  2015-03-01       Impact factor: 3.084

Review 6.  Partial remission, residual symptoms, and relapse in depression.

Authors:  E S Paykel
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

7.  Patient learning of treatment contents in cognitive therapy.

Authors:  Nicole B Gumport; Lu Dong; Jason Y Lee; Allison G Harvey
Journal:  J Behav Ther Exp Psychiatry       Date:  2017-08-31

8.  A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned.

Authors:  Charles H Bombardier; Jesse R Fann; Catherine S Wilson; Allen W Heinemann; J Scott Richards; Ann Marie Warren; Larry Brooks; Catherine A Warms; Nancy R Temkin; Denise G Tate
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

9.  Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial.

Authors:  Manish K Jha; Abu Minhajuddin; Tracy L Greer; Thomas Carmody; A John Rush; Madhukar H Trivedi
Journal:  Am J Psychiatry       Date:  2016-08-13       Impact factor: 18.112

10.  ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression.

Authors:  A Ray; L Tennakoon; J Keller; J E Sarginson; H S Ryan; G M Murphy; L C Lazzeroni; M H Trivedi; J H Kocsis; C DeBattista; A F Schatzberg
Journal:  Pharmacogenomics J       Date:  2014-12-09       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.